KBC

ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France

Retrieved on: 
Thursday, March 21, 2024
Offerings, Public, Private, Brussels Stock Exchange, KBC, Euronext, DSM-IV codes, CSO, Euronext Amsterdam, NOT, SCI, Movement, Hand, Security (finance)

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Key Points: 
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • “We are delighted to announce the successful capital raise of €20 million, including a fully subscribed upsize option despite challenging market conditions,” said Dave Marver, CEO of ONWARD Medical.
  • Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333 shares respectively allocated to INKEF Capital and EQT Life Sciences.
  • Following the Offerings, INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s share capital.

SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT

Retrieved on: 
Thursday, March 21, 2024
Cardiorenal syndrome, EUR, Partner, DSR, Offering, Liver disease, Ketel One, KBC, Patient, 2.0, Cancer, Quality management system, AMERICA, Prospectus, Heart failure, EQT, LSP, PMA, US FDA, NASH, Overload, THT, USD, FDA, Security (finance)

This is an exciting time for Sequana Medical as the US FDA's review of our alfapump® PMA filing progresses and we continue our preparations for US commercial launch.

Key Points: 
  • This is an exciting time for Sequana Medical as the US FDA's review of our alfapump® PMA filing progresses and we continue our preparations for US commercial launch.
  • We look forward to continuing our track record of meeting our corporate milestones and driving Sequana Medical forward."
  • (ii)   Finalizing the North American pivotal study in recurrent and refractory liver ascites (POSEIDON) towards secondary endpoint readout planned for Q2 2024.
  • As announced in February 2024, the Company entered into an unsecured and subordinated convertible loan agreement with Partners in Equity and Rosetta Capital for an aggregate principal amount of EUR 3.0 million.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Brussels Stock Exchange, SCI, Public, Private, KBC, VWAP, ARC, Hand, Acceleration, Regulation, DSM-IV codes, CSO, Movement, EUR, Private placement, BCI, Offerings, Public offering, Equity carve-out, Euronext, Issue, Euronext Amsterdam, Security (finance)

The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.

Key Points: 
  • The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • “It is the Company’s intention to raise gross proceeds of indicatively EUR 15 million from the Offerings, with an up to EUR 5 million upsize option.
  • A separate announcement will be made shortly regarding the Public Offer in France via the PrimaryBid platform and its terms.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND PROVIDES TRADING UPDATE

Retrieved on: 
Wednesday, March 20, 2024
EUR, Partner, Tax, DSR, Offering, Liver disease, FY, Ketel One, KBC, International, Committee, Financial services, 2.0, Cancer, Quality management system, AMERICA, Prospectus, Heart failure, FSMA, Person, European, EQT, LSP, PMA, US FDA, Overload, Stock, Marketing, Transaction, Security (finance)

(ii)   Finalizing the North American pivotal study in recurrent and refractory liver ascites (POSEIDON) towards secondary endpoint readout planned for Q2 2024.

Key Points: 
  • (ii)   Finalizing the North American pivotal study in recurrent and refractory liver ascites (POSEIDON) towards secondary endpoint readout planned for Q2 2024.
  • The Offering shall be structured as a private placement of new shares via an accelerated bookbuilding, which will commence immediately.
  • Trading in Sequana Medical shares on the regulated market of Euronext Brussels will be suspended during the bookbuilding period.
  • Trading in the shares is expected to resume following the publication of the results of the Offering.

MICLEDI Microdisplays Raises Series A Funding to Advance Best-in-Class microLED Display Design and Manufacturing

Retrieved on: 
Tuesday, March 12, 2024
CMOS, Aluminium gallium indium phosphide, ASIC, Augmented reality, Application-specific integrated circuit, SPIE, KBC, Tier 1, RGB, GF, PMV, CES, Series, GlobalFoundries, MicroLED, Television

Series A follows a significant seed round award and additional non-dilutive funding in the form of grants and other vehicles from VLAIO.

Key Points: 
  • Series A follows a significant seed round award and additional non-dilutive funding in the form of grants and other vehicles from VLAIO.
  • This brings the company’s total funding to date to nearly $30 million.
  • “The company’s achievements during this seed round have been astounding,” said Sean Lord, CEO of MICLEDI.
  • Seed funding also enabled the company to prove best-in-class blue and green GAN-based microLED arrays with pixel-by-pixel microlenses in its unique 300mm flow.

KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share

Retrieved on: 
Friday, February 9, 2024
KBC, Target, Target price, Buy, Euronext, BCI, Movement, EUR, SCI, ARC, Research, Cryptocurrency

EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share.

Key Points: 
  • EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share.
  • This is a premium of 161% to the closing price of EUR 3.83 on February 8, 2024.
  • KBC joins three other banks whose research analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price.
  • “KBC Securities’ initiation of coverage reflects strong confidence in our ability to achieve this year’s milestones, which include the planned commercialization of our ARC-EX® platform later this year,” said Dave Marver, CEO of ONWARD Medical.

Energy Capital Vietnam Signs Six Memoranda of Understanding During the Asia-Pacific Cooperation Leaders’ Week 2023 Conference

Retrieved on: 
Friday, December 1, 2023
Microsoft, Policy, Conference, ECV, Green infrastructure, Partnership, University, Research, POLA, Semiconductor, Green Alliance, MOU, Hospital, Private sector, PTE, Innovation Center station, Innovation, Internet of things, Artificial intelligence, Corridor, Transport, Carbon, Investment, Urbanization, KBC, Port, Renewable energy

HOUSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Energy Capital Vietnam (ECV), a project development and holding company established as a platform for direct investment into energy and infrastructure within Vietnam, signed six memoranda of understanding (MOU) in San Francisco during the Asia-Pacific Cooperation Leaders’ Week 2023 Conference.

Key Points: 
  • HOUSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Energy Capital Vietnam (ECV), a project development and holding company established as a platform for direct investment into energy and infrastructure within Vietnam, signed six memoranda of understanding (MOU) in San Francisco during the Asia-Pacific Cooperation Leaders’ Week 2023 Conference.
  • These six agreements represent ECV’s ability to assemble a diverse set of partners and mobilize them to provide American expertise to Vietnam.
  • ECV, SaigonTel, and KBC will develop ports, energy services breakbulk and storage, liquid and dry bulk storage, and adjacent facilities.
  • Energy security remains paramount as Vietnam seeks to integrate deeper into global supply chains, especially for semiconductors and other hi-tech sectors.

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

Retrieved on: 
Monday, November 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Infectious Diseases, Technology, Annual general meeting, Euronext Paris, Audit committee, CFO, KBC, Brussels Stock Exchange, Committee, Therapy, Remuneration, Oncocyte, Growth, Investment banking, Management, IPA

As CEO and Chairman of SmartHealth Dx since 2022, Levine has focused the company’s strategy, operational efficiency, and boosted corporate value.

Key Points: 
  • As CEO and Chairman of SmartHealth Dx since 2022, Levine has focused the company’s strategy, operational efficiency, and boosted corporate value.
  • His background also includes a foundational role at The Shemano Group, a San Francisco-based investment bank focused on technology and life sciences sectors.
  • Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, lauds Levine’s combination of life sciences and financial acumen as invaluable for IPA.
  • The financial results will be issued in a press release prior to the call.

EQS-News: CANCOM SE: Significant revenue and gross profit growth in the first half-year

Retrieved on: 
Thursday, August 10, 2023
International, Tata Business Support Services, EBITA, KBC, RTÉ Executive Board, EBITDA, Acquisition, SE, Growth, CANCOM, Music, Video game

At Group level, revenue amounted to € 647.0 million (previous year: € 595.5 million) and gross profit rose by 15.7 percent to € 245.2 million (previous year: € 212.0 million).

Key Points: 
  • At Group level, revenue amounted to € 647.0 million (previous year: € 595.5 million) and gross profit rose by 15.7 percent to € 245.2 million (previous year: € 212.0 million).
  • Gross profit amounted to € 214.0 million (previous year: € 195.3 million) and EBITDA reached € 32.4 million (previous year: € 44.5 million).
  • In Consulting, revenue was € 115.6 million (previous year: € 93.6 million) and gross profit was € 91.0 million (previous year: € 74.0 million) with a gross profit margin of 78.7 percent.
  • In Support Services, revenue in the same period reached € 34.9 million (previous year: € 24.6 million) and with gross profit of € 23.2 million (previous year: € 18.1 million), the gross profit margin was 66.6 percent.